

PRECEPTORSHIP PROGRAMME

Advanced Non Resectable Hepatocellular Carcinoma, Biliary and Pancreatic Cancer

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

**PARIS
FRANCE**

6-7 DECEMBER 2019

Co-Chairs

Konstantinos Kamposioras, UK
Julien Taieb, FR

ESMO PRECEPTORSHIP PROGRAMME

ADVANCED NON RESECTABLE HEPATOCELLULAR CARCINOMA, BILIARY AND PANCREATIC CANCER

Multidisciplinary management, standards of care, therapeutic targets
and future perspectives

Paris, France
6-7 December 2019

CO-CHAIRS:

Konstantinos Kamposioras, United Kingdom
Julien Taieb, France

SPEAKERS:

Thierry de Baere, France	Somnath Mukherjee, United Kingdom
George Bozas, United Kingdom	Valérie Paradis, France
Jérôme Cros, France	Gerald Prager, Austria
Pierre H. Deprez, Belgium	Antonio Sa Cunha, France
Michel Ducreux, France	Bruno Sangro, Spain
Karin Jordan, Germany	Valérie Vilgrain, France

LEARNING OBJECTIVES

- To understand epidemiology, aetiology and molecular biology of hepatocellular carcinoma (HCC), biliary and pancreatic cancers
- To understand multidisciplinary management and treatment of advanced non resectable hepatocellular carcinoma, biliary and pancreatic cancers
- To learn about advances in the treatment and novel targets in hepatobiliary (HPB) carcinomas
- To address complex cases management frequently encountered in daily practice related with these diseases

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 6 December 2019

09:00-09:15 15'	Welcome and Introduction	Konstantinos Kamposioras, UK Julien Taieb, FR
09:15-10:55 100'	SESSION 1 Pancreatic cancer – Part I	Chair: Julien Taieb, FR
25'	Epidemiology, molecular characterisation and hereditary forms of pancreatic cancer	Jérôme Cros, FR
25'	Upfront radiologic staging and restaging assessment	Valérie Vilgrain, FR
25'	Locally advanced pancreatic cancer (LAPC): To palliate or to cure?	Julien Taieb, FR
25'	The role of RT in non resectable pancreatic cancer	Somnath Mukherjee, UK
10:55-11:25	Coffee break	
11:25-13:35 130'	SESSION 2 Pancreatic cancer – Part II	Chair: Michel Ducreux, FR
25'	Systemic treatment of metastatic pancreatic cancer: First-line	Michel Ducreux, FR
25'	Systemic treatment of metastatic pancreatic cancer: Second-line and treatment sequence	Julien Taieb, FR
25'	Ongoing research and perspectives in advanced pancreatic cancer	Gerald Prager, AT
25'	Supportive care in pancreatic and HPB malignancies (cachexia, exercise, pain management, Patient Reported Outcome Measures, antiemesis, prophylaxis of VTE, skin toxicity)	Karin Jordan, DE
30'	Participants clinical case discussion (2x15')	Faculty
13:35-14:35	Lunch	
14:35-16:15 100'	SESSION 3 Biliary tract cancers (BTCs)	Chair: Julien Taieb, FR
25'	Molecular classification of BTCs and clinical relevance	Valérie Paradis, FR
25'	First-line treatment in advanced BTCs and the continuum of care	Konstantinos Kamposioras, UK
25'	Future directions in the management of advanced BTCs	Michel Ducreux, FR
25'	The role of radiological techniques in advanced BTCs (RT, SIRT, SBRT, cryotherapy, microwave)	Thierry de Baere, FR
16:15-16:45	Coffee break	
16:45-18:05 80'	SESSION 4 Transversal topics for advanced HPB malignancies – Part I	Chair: Konstantinos Kamposioras, UK
25'	The role of endoscopy in HPB cancers: From diagnosis to palliation	Pierre H. Deprez, BE
25'	Chemotherapy for difficult cases: Jaundice, cirrhosis, liver transplantation, HBV, HCV infection	Konstantinos Kamposioras, UK
30'	Participants clinical case discussion (2x15')	Faculty
18:05-18:35 30'	SPECIAL LECTURE	Chairs: Konstantinos Kamposioras, UK Julien Taieb, FR
30'	Thromboembolic complications and paraneoplastic manifestations in pancreaticobiliary cancers: From prevention to treatment	George Bozas, UK
20:30	Dinner	

Saturday, 7 December 2019

08:30-10:30 120'	SESSION 5 HCC	Chair: Bruno Sangro, ES
30'	Epidemiology and pathology of HCC	Valérie Paradis, FR
30'	Systemic treatment of HCC in the era of immunotherapy	Bruno Sangro, ES
30'	Locoregional treatment of unresectable HCC	Thierry de Baere, FR
30'	Emerging immunotherapy and future directions in unresectable HCC	Bruno Sangro, ES
10:30-11:00	Coffee break	
11:00-11:25 25'	SESSION 6 Transversal topics for advanced HPB malignancies – Part II	Chair: Konstantinos Kamposioras, UK
25'	The role of the surgeon in advanced pancreaticobiliary cancers (from palliative resection to transplantation)	Antonio Sa Cunha, FR
11:25-12:10 45'	SESSION 7 Participants clinical case discussion	Chairs: Konstantinos Kamposioras, UK Julien Taieb, FR
45'	Participants clinical case discussion (3x15')	Faculty
12:10-12:25 15'	Conclusion and farewell	Konstantinos Kamposioras, UK Julien Taieb, FR
12:25-13:30	Lunch	

Note: Each 15 minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion